Teva Presents New Data for SD-809 in Huntington Disease at 68th American Academy of Neurology (AAN) Annual Meeting in Vancouver, B.C.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. DFTX
10. NKE

Go back to Teva Presents New Data for SD-809 in Huntington Disease at 68th American Academy of Neurology (AAN) Annual Meeting in Vancouver, B.C.

Guggenheim Remains Bullish Ahead of Teva Pharma's (TEVA) AGN Deal

April 18, 2016 11:38 AM EDT

Guggenheim reiterated a Buy rating and $80.00 price target on Teva Pharma (NYSE: TEVA) ahead of a deal close and pipeline catalysts in 2016. The company's AGN generics deal is scheduled to close in June. Guggenheim Cut 2016 EPS estimates $0.35 to $5.17. The decreases in EPS estimates are... More